{"title":"Symptomatic and Ultrasonographic Improvement in Rheumatoid Arthritis Temporally Associated with Intravenous NAD<sup>+</sup> Therapy: A Case Report.","authors":"Mohamad Rabih Itani, Arije Farhat, Nour Abou Yehya, Lana Ghraizi, Bahaa Bou Dargham","doi":"10.1002/acr2.90151","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Altered NAD<sup>+</sup> metabolism has been described in rheumatoid arthritis (RA), but intravenous NAD<sup>+</sup> has not been clinically evaluated for inflammatory arthritis.</p><p><strong>Case presentation: </strong>A 49-year-old woman with a rheumatologist-documented diagnosis of RA had progressive polyarthralgia, intermittent swelling, marked morning stiffness, and baseline hand and wrist ultrasonography showing active synovitis. After approximately 4 months of inconsistently taken methotrexate, discontinued because of adverse effects, she received four intravenous NAD<sup>+</sup> infusions for aesthetic and antiaging purposes: 250 mg in 500 mL of 0.9% sodium chloride over approximately 1 hour every 2 weeks. She reported rapid pain relief after individual infusions and subsequent improvement in swelling, morning mobility, function, and analgesic use. No infusion-related adverse events were reported. Nine months later, follow-up ultrasonography showed no synovitis or Doppler hyperemia. Psychologic support, exercise, and improvement in personal circumstances occurred concurrently.</p><p><strong>Conclusion: </strong>The symptomatic and ultrasonographic changes were temporally associated with intravenous NAD<sup>+</sup>, but incomplete diagnostic documentation, previous methotrexate exposure, concurrent psychosocial changes, and the uncontrolled retrospective design preclude causal inference. This case is hypothesis-generating and supports prospective controlled investigation.</p>","PeriodicalId":93845,"journal":{"name":"ACR open rheumatology","volume":"8 9","pages":"e90151"},"PeriodicalIF":2.9000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13583921/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACR open rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/acr2.90151","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Altered NAD+ metabolism has been described in rheumatoid arthritis (RA), but intravenous NAD+ has not been clinically evaluated for inflammatory arthritis.
Case presentation: A 49-year-old woman with a rheumatologist-documented diagnosis of RA had progressive polyarthralgia, intermittent swelling, marked morning stiffness, and baseline hand and wrist ultrasonography showing active synovitis. After approximately 4 months of inconsistently taken methotrexate, discontinued because of adverse effects, she received four intravenous NAD+ infusions for aesthetic and antiaging purposes: 250 mg in 500 mL of 0.9% sodium chloride over approximately 1 hour every 2 weeks. She reported rapid pain relief after individual infusions and subsequent improvement in swelling, morning mobility, function, and analgesic use. No infusion-related adverse events were reported. Nine months later, follow-up ultrasonography showed no synovitis or Doppler hyperemia. Psychologic support, exercise, and improvement in personal circumstances occurred concurrently.
Conclusion: The symptomatic and ultrasonographic changes were temporally associated with intravenous NAD+, but incomplete diagnostic documentation, previous methotrexate exposure, concurrent psychosocial changes, and the uncontrolled retrospective design preclude causal inference. This case is hypothesis-generating and supports prospective controlled investigation.